The first half of the chemical drug TOP20 came out! Heng Rui, Yang Zijiang and Qilu were promoted to the top 10.

According to the latest data from Minernet, the market for public hospital drugs in key cities in the first half of 2020 was affected by the new crown epidemic, with sales down 17.33 percent year-on-year.
From the TOP20 manufacturers, domestic pharmaceutical companies occupy 8 seats, of which Hengrui, Yangzijiang, Qilu 3 among the top 10; Dzosin injections to occupy the first place, Zhengda Tianqing Pharmaceutical Group's anti-tumor class 1 new drug atrotini capsule growth rate is staggering, while Roche is known as the "troika" of curto-pearl monoanti, beval-pearl mono-resistance, lytoxi-single resistance due to the impact of bio-similar drugs, sales fell sharply.
HengRui, Yangzijiang, Qilu "grab food" 70 billion market, is the big day to catch up with the recent key cities public hospital chemical drug sales (units: billion yuan) Source: key city public hospitals chemical drug terminal competition pattern Mi net Data show that in recent years, the market for public hospital drugs in key cities has grown steadily, with sales reaching nearly 180 billion yuan in 2019 and more than 70 billion yuan in the first half of 2020 affected by the new crown epidemic, but down 17.33 percent year-on-year.
In the first half of 2020, the city pattern of chemical drugs in key cities public hospitals (units: 100 million yuan) Source: The competitive pattern of chemical drug terminals in key cities from the urban pattern, the top three Shanghai, Guangzhou, Beijing sales stand out.
, Shanghai and Guangzhou both have sales of more than 8 billion yuan, while Beijing, in third place, and Zhengzhou, fourth, have sales of nearly 2 billion yuan.
In the first half of 2020, key urban public hospitals TOP20 manufacturers sales pattern source: key cities public hospitals chemical drug terminal competition pattern from top20 manufacturers, domestic pharmaceutical companies have Hengrui, Yangzijiang, Qilu, Zhengda Tianqing, Shi Medicine, such as 8.
in the top 10, foreign pharmaceutical companies occupy 7 seats, domestic pharmaceutical companies only Hengrui, Yangzijiang, Qilu 3.
brand TOP20! Yangzijiang "break out", anti-tumor and immunomodulants accounted for half of the first half of 2020 key urban public hospital chemical brand TOP20 source: key city public hospital chemical terminal competition pattern brand TOP20, anti-tumor and immunomodulants the most, there are 10;
Among them, Yangzijiang's Dzosin injections occupy the first place, Zhengda Tianqing Pharmaceutical Group's anti-tumor class 1 new drug atrotini capsule growth is staggering, while Roche is known as the "troika" of curto-pearl monoantitor, beva-pearl mono-resistance, lysoxi mono-resistance due to the impact of bio-similar drugs, sales fell sharply.
In recent years, the sales of diazepin injections in key urban public hospitals (units: 100 million yuan) Source: Key city public hospitals chemical terminal competition pattern Zosin by Wyeth-Ayerst laboratory research and development, adaptive disorders for the need to use opioid analgesics to treat a variety of pain.
meters intranet data show that in recent years in key cities, public hospitals, Zosin injection sales hit a new high, after breaking the 1 billion mark, maintained steady growth;
, only Yangzijiang Pharmaceuticals and Nanjing Yuke Pharmaceuticals have passed the consistent evaluation.
, Yangzijiang's market share is the leading, and Nanjing Yuke Pharmaceutical was approved at the end of last year, has not yet formed a sales scale.
addition, Enhua Pharmaceuticals and Tianjin Pharmaceutical Research Institute submitted listing applications in categories 3 and 4 respectively in the review and approval, after approval will be treated as passing a consistent evaluation.
Recently, the State Health Insurance Administration issued the "2020 National Health Insurance Drug Catalog Adjustment through the form of examination of the list of declared drugs", the Zosin injection is listed, there are industry analysts pointed out that whether to enter the catalog is mainly to see the pricing strategy of enterprises and price reduction range.
In recent years, the sales of qutoju single resistance/bevazhu single resistance/lytoxi single anti-injection agents in key urban public hospitals (units: 100 million yuan) Source: In July, Roche disclosed the first half of 2020 results, among which, known as Roche 's "troika" qutoju single resistance, beva bead single resistance, lysoxi single resistance due to the impact of bio-similar drugs, sales fell sharply.
meters of intranet data show that in the first half of 2020 key city public hospitals Roche "troika" although in the brand TOP10 occupied three seats, but sales showed a sharp decline, among them, Beva zhu single anti-injection decreased by more than 10% yoY;
From the manufacturer's point of view, up to now, the injection of crater bead single resistance has Roche and Fuhong Hanyu two;
, with the strength of domestic pharmaceutical companies, Roche "troika" a unique situation was broken.
In recent years, the sales of Arotini capsules in key urban public hospitals (units: 100 million yuan) Source: Key cities public hospitals chemical terminal competition pattern Atrotini capsules hydrochloric acid is China's biopharmaceutical subsidiary Zhengda Tianqing Pharmaceutical Group developed anti-tumor class 1 new drugs.
meters of intranet data show that in recent years, key city public hospitals Androtini capsule sales have grown rapidly, in 2018 listed sales have been close to 30 million yuan;
Biopharmaceuticals said the launch of hydrochloric acid atrotini capsules has provided an effective new treatment for patients with advanced non-small cell lung cancer in China.
, we need to take full advantage of Theronini's success and focus on the field of cancer.
source: Mi Net database, the company announced the original title: the first half of the chemical drug TOP20 out! Hengrui, Yangzijiang, Qilu "grab food" 70 billion market, Roche "troika" again hit.